2 hours ago
3
Skip to navigation Skip to main contented Skip to close file
TipRanks
Tue, January 27, 2026 astatine 7:16 AM CST 1 min read
Arcutis Biotherapeutics (ARQT) announced that connected January 23, 2026, the Company and Kowa Pharmaceuticals America mutually agreed to terminate their promotion agreement. The statement covered income and promotion of ZORYVE by Kowa to superior attraction physicians and pediatricians successful the United States. Following the termination, Arcutis plans to presume work for income and promotion of ZORYVE successful the pediatric and superior attraction settings. The Company is finalizing its plans for promotion to these clinicians and volition supply further updates during the Q4 net telephone connected February 25, 2026. This inaugural is chiseled from and successful summation to the targeted enlargement of the Company’s dermatology salesforce, which volition stay focused connected serving dermatology clinicians and increasing prescriptions of ZORYVE successful dermatology practices.
-
Unlock hedge fund-level information and almighty investing tools for smarter, sharper decisions
-
Stay up of the marketplace with the latest quality and investigation and maximize your portfolio's potential
Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>
See Insiders’ Hot Stocks connected TipRanks >>
Read More connected ARQT:
Disclaimer & DisclosureReport an Issue
-
Arcutis announces results of survey connected inflammatory tegument conditions
-
Buy Rating connected Arcutis Biotherapeutics Driven by Zoryve Commercial Momentum, Pipeline Upside, and Favorable Risk‑Reward Valuation
-
Arcutis Biotherapeutics: Strengthening Zoryve Franchise, Approaching Profitability, and Multiple 2026+ Pipeline Catalysts Support Buy Rating
-
Arcutis Biotherapeutics sees FY26 ZORYVE gross $455M-$470M
-
Sustained Zoryve Prescription Momentum and Broad Dermatology Portfolio Underpin Buy Rating and $37 Target connected Arcutis Biotherapeutics
English (CA) · 
English (US) · 
Spanish (MX) ·